Ellevest Inc’s Veracyte VCYT Stock Holding History

Ellevest Inc’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-160	Closed	-$3.57K	–	1574
2023 Q1	$3.57K	Buy	160 +44	+38%	+$1.06K	﹤0.01%	1306
2022 Q4	$2.75K	Buy	116 +105	+955%	+$2.44K	﹤0.01%	1325
2022 Q3	$0	Buy	+11	New	+$248	﹤0.01%	1871
2021 Q2	–	Sell	-13	Closed	-$1K	–	1424
2021 Q1	$1K	Buy	+13	New	+$749	﹤0.01%	1210

Other funds holding VCYT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ellevest Inc's VCYT Position: Q2 2023 in Review

Ellevest Inc sold out of Veracyte (VCYT) in Q2 2023, closing a stake of 160 shares — an estimated $3.57K sold.

Ellevest Inc first reported a position in VCYT in Q1 2021 and held it in 4 quarters. The position peaked at $3.57K in Q1 2023. 232 funds tracked by Wall St. Rank hold VCYT as of Q2 2023.

Ellevest Inc reported no remaining Veracyte position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 160 Veracyte shares in Q2 2023, an estimated $3.57K.
Ellevest Inc first reported a position in Veracyte in Q1 2021 and held it in 4 quarters.
Ellevest Inc's Veracyte position peaked at $3.57K in Q1 2023.
232 funds tracked by Wall St. Rank held Veracyte as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.